FDA’s Digital Health Guru Stepping Away From Agency

Bakul Patel, who announced on 30 April that he will be moving on from the US FDA, leaves behind a legacy of innovation.

Behtany Hills and Bakul Patel
LIFE SCIENCE ATTORNEY BETHANY HILLS AND THE FDA'S BAKUL PATEL TALK ABOUT THE FUTURE OF DIGITAL HEALTH AT THE 2019 WORLD MEDICAL INNOVATION FORUM IN BOSTON • Source: Ferdous Al-Faruque

After more than 13 years at the US Food and Drug Administration, Bakul Patel, the agency’s digital health guru, has stepped down.

Patel announced his departure on his LinkedIn page.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Regulation

Medical Device Recalls Down In Q1 For Lowest Quarterly Count In 3 Years. But Will It Last?

 

Despite a surge in product recalls across five key industries in the first quarter of the year, medical device recalls were down, according to Sedgwick’s latest recall index. But the firm noted they’ve since ticked up.

23andMe Genetic Tests Among 12 New FDA Classifications

 
• By 

A late-August batch of device classifications from the US FDA includes genetic tests from 23andMe, hand-held spinal surgery tools, and several IVDs.

Why EU Innovators Face Growing Barriers With EU Combination Product Regulation

 

Combination products are no longer fringe – they are the “new normal,” consultant Stephen O’Rourke told Medtech Insight. The EU has the expertise to handle the regulatory complexity, but only if connects the dots between silos. That’s the challenge, he said, and the opportunity.

UK MHRA Ready To Evolve Approach To In-House Manufactured Medtech

 
• By 

The UK device regulator wants to align health institution device exemptions with its evolving policy of agile regulation of medtech in the British market. It asks stakeholders to complete a survey by Sept. 15.

More from Policy & Regulation

Medical Device Recalls Down In Q1 For Lowest Quarterly Count In 3 Years. But Will It Last?

 

Despite a surge in product recalls across five key industries in the first quarter of the year, medical device recalls were down, according to Sedgwick’s latest recall index. But the firm noted they’ve since ticked up.

Dexcom Nabs Weight Management Indication For Signos CGM

 

Signos links users to Dexcom’s Stelo for glucose readings and historic trends. The app is available in iOS and Android from the firm’s website, where it’s priced at $139 for three-month plan and $129 for a two-month plan, or online app stores.

German Health Researchers Prep for Possible Disruptions to PubMed, ClinicalTrials.gov

 

IQWiG, Germany’s health technology assessment body, is making contingency plans in case key US resources it relies on for information retrieval, when conducting benefit assessments of new medicines, become unavailable.